AbCellera (Nasdaq: ABCL) will announce its second quarter 2026 financial results on Wednesday, August 5, 2026, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern...
AbCellera (Nasdaq: ABCL) today announced the appointment of Lynn Seely, M.D., to its Board of Directors as an independent director. “Dr. Seely is a respected executive leader with...
The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any program Jazz exercises options to develop
The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any program Jazz exercises its option to develop ...
AbCellera (Nasdaq: ABCL) today announced the appointment of Victor Sandor, M.D.C.M, to its Board of Directors as an independent director. “Dr. Sandor is an experienced director...
AbCellera Biologics (NASDAQ:ABCL) is emphasizing its transition from a partner-based antibody discovery business to a proprietary drug development company, Chief Financial Officer Andrew Booth said during...
AbCellera Biologics (NASDAQ:ABCL) said its first quarter of 2026 was marked by progress in its internal drug pipeline, including interim Phase 1 data for its lead program, ABCL635, and continued preparation...
ABCL635 demonstrated a favorable tolerability profile, with no observed liver toxicity, and achieved potent and sustained reductions in biomarkers of target engagement. ...
Barchart Research What to Expect from ABCL Earnings ABCL Generated May 8, 2026 Current Price $5.24 EPS Estimate $$-0.22 Consensus Rating Strong Buy Average Move 5.73% AbCellera's ABCL635 Phase One Data...
Barchart Research What to Expect from ABCL Earnings ABCL Generated May 8, 2026 Current Price $5.24 EPS Estimate $$-0.22 Consensus Rating Strong Buy Average Move 5.73% AbCellera's ABCL635 Phase One Data...